Retatrutide, a novel dual agonist of the GLP-1 receptor and glucose-dependent secreted polypeptide (GIP) receptor , is showing promising outcomes in preliminary clinical trials . Current examination https://lingeriebookmark.com/story11378555/retatrutide-emerging-investigations-and-possible-clinical-uses